Results 101 to 110 of about 6,428 (208)

Risk of Depressive Episodes with Rimonabant

, 2011
Background: Marketing authorization for rimonabant was withdrawn in October 2008, mainly because the psychiatric adverse effects could not be addressed by further risk minimization.Objective: The aim of the study was to compare the risk of major and ...
Lynda Wilton, Saad A.W. Shakir, Buggy, Yvonne, Cornelius, Victoria, Victoria Cornelius, Wilton, Lynda, Shakir, Saad A. W., Yvonne Buggy   +7 more
core   +1 more source

Rehabilitating rimonabant [PDF]

Journal of Molecular Medicine, 2013
openaire   +2 more sources

Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats

, 2010
The cannabinoid receptor 1 antagonist, rimonabant, reduces food intake and body weight, but contradictory findings have been reported as to whether the weight-reducing effect is fully accounted for by the reduced food intake or if rimonabant also ...
Malmlöf, Kjell,, Sveriges lantbruksuniversitet.   +1 more
core   +1 more source

Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.

, 2009
BACKGROUND: Emotional processing measures are sensitive to acute administration of clinically useful antidepressant drugs. We wished to test the hypothesis that these models would also be able to detect agents likely to cause depression as an adverse ...
Horder, J, Di Simplicio, M, Browning, M, Browning, Michael, Harmer, Catherine, Harmer, CJ, Cowen, PJ   +6 more
core   +1 more source

The CB1 receptor agonist WIN 55,212-2 fails to evoke physical dependence in Swiss mice

Current Issues in Pharmacy and Medical Sciences
Potential ability of cannabinoids to produce dependence is still a controversial issue. In our study, in order to examine the cannabinoid physical dependence phenomenon we administered CB1 receptor agonist WIN55,212-2, afterwards, in order to ...
Barbara Budzyńska, Grażyna Biała
doaj  

Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

, 2010
Background and purpose: There is growing evidence that the cannabinoid CB(1) receptor antagonist, rimonabant (SR141716) exerts potential anti-proliferative and anti-inflammatory actions. Here, we have assessed the effects of rimonabant in vitro in murine
Malfitano AM, Sosa S, Laezza C, De Bortoli M, Bifulco M, Tubaro A   +5 more
core  

Sterol carrier protein 2 loss reduces anxiety and enhances fear extinction. [PDF]

J Affect Disord
Liedhegner ES, Stuhr KL, Doncheck EM, Tinklenberg J, Pollock S, Sterrett J, Gunduz-Cinar O, Hillard CJ.   +7 more
europepmc   +1 more source

Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes

, 2007
peer reviewedRimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including above 6.600 overweight/obese patients with ...
Van Gaal, L. F., Scheen, André
core  

Involvement of CB1 cannabinoid receptors in methamphetamine-related decision-making and social behavior deficits. [PDF]

BMC Neurosci
Mousavi T, Hatami N, Niknamfar S, Naseri M, Rafaiee R, Tamijani SMS, Ranaiy MS, Ghazvini H.   +7 more
europepmc   +1 more source

Endocannabinoid system and skeletal muscle health: Insights from cannabidiol. [PDF]

Mol Metab
Deglos A, Saroul N, Walrand S, Le Bacquer O.   +3 more
europepmc   +1 more source